Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
About Ultragenyx Pharmaceutical Inc.
Founded in 2010, Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Where others turn away or take the road well traveled, we run towards the unknown and blaze new trails. We’re working hard to create treatments where none exist, giving new hope to patients with rare genetic diseases. Because you can only make a meaningful impact when your team has big ambitions. Join Ultragenyx and put your passion to work.
ultrafocused
Ultragenyx is dedicated to fostering a workplace environment that keeps our team inspired and provides the vision, resources and support they need to succeed. That includes maintaining a healthy, inclusive company culture where employees feel respected and valued. And providing opportunities for learning, personal growth, and career advancement. At Ultragenyx we push each other to perform at our very best, because we never lose sight of our mission – to make a difference in our patients’ lives.
212 articles with Ultragenyx Pharmaceutical Inc.
-
Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
6/19/2019
Scope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeutics
-
Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer
6/17/2019
Ultragenyx Pharmaceutical Inc. announced it has promoted Erik Harris to Executive Vice President and Chief Commercial Officer, effective June 11, 2019.
-
Ultragenyx to Present at Upcoming June 2019 Investor Conferences
6/2/2019
Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences
-
Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award
5/29/2019
Ultragenyx Pharmaceutical Inc. announced that the Biotechnology Innovation Organization (BIO) has awarded this year’s Henri A. Termeer Biotechnology Visionary Award to Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer, President and founder of Ultragenyx.
-
Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
5/6/2019
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States
-
Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update
4/30/2019
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Monday, May 6, 2019 at 5pm ET to discuss first quarter 2019 financial results and provide a corporate update.
-
Two years after its acquisition of Dimension Therapeutics, Bay Area-based Ultragenyx Pharmaceutical, Inc. continues to see success in its clinical programs for the company’s adeno-associated virus (AAV) gene therapy treatments and in its overall growth.
-
Ultragenyx Announces UX007 Granted Fast Track Designation and Rare Pediatric Disease Designation by U.S. FDA for Treatment of Long-Chain Fatty Acid Oxidation Disorders
4/16/2019
Company on Track to Submit NDA to FDA in Mid-2019
-
Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York
4/11/2019
Ultragenyx Pharmaceutical Inc. announced that management and external experts will provide an update to the investment community on the global commercial launch of Crysvita®, the company’s gene therapy programs and platform including manufacturing capabilities, and preclinical data on the next three Investigational New Drug applications the company plans to submit to the U.S. Food and Drug Administration.
-
Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children
3/26/2019
First Latin American Approval of Crysvita, the only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease
-
Ultragenyx to Present at Upcoming March 2019 Investor Conferences
3/11/2019
Ultragenyx Pharmaceutical Inc. today announced that it will present at the following upcoming investor conferences:
-
Ultragenyx Announces Proposed Public Offering of Up to $250,000,000 of Its Shares Common Stock
2/25/2019
Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock.
-
Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
2/21/2019
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients
-
Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update
2/19/2019
Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter
-
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
2/14/2019
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
-
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update
2/12/2019
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018.
-
Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors
2/4/2019
Ultragenyx Pharmaceutical Inc. announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019.
-
Ultragenyx Announces Positive Topline Data from Ongoing Long-Term Extension Study of UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders
1/22/2019
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced positive topline data from an ongoing long-term extension study of UX007 in patients with long-chain fatty acid oxidation disorder (LC-FAOD), demonstrating sustained reductions in the duration and frequency of major clinical events (MCE) and a long-term safety profile similar to what has previously been seen with UX007.
-
Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
1/4/2019
DTX401 Response Observed in All Three Patients, with Two Patients Demonstrating Clinically Meaningful Improvement in Time to Hypoglycemia
-
Ultragenyx to Present at the 37th J.P. Morgan Healthcare Conference
1/3/2019
Ultragenyx Pharmaceutical Inc. today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 37TH Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 4:00 pm PT in San Francisco.